Therapeutic effect of TRC105 and decitabine combination in AML xenografts

Therapeutic effect of TRC105 and decitabine combination in AML xenografts

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy, often characterized by poor prognosis following standard induction therapy. The hypomethylating agent decitabine (DAC) is an alternative treatment for elderly and relapsed/refractory AML patients, yet responses following DAC monot...

Full description

Bibliographic Details
Main Authors: June Baik, Martin Felices, Ashley Yingst, Charles P. Theuer, Michael R. Verneris, Jeffrey S. Miller, Rita Perlingeiro
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:Heliyon
Subjects:
AML
TRC105
Decitabine
Xenografts
Cell biology
Antibody
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844020320855

Internet

http://www.sciencedirect.com/science/article/pii/S2405844020320855

Similar Items